Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial

Volz, Hans-Peter; Möller, Hans‐Jürgen; Reimann, I. W.; Stoll, Klaus-Dieter

doi:10.1016/s0924-977x(00)00074-2

Cited by 91 publications

(44 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[3][4][5][6] Some medically unexplained symptoms (presumed psychogenic) have been shown to be responsive to pharmacologic interventions. [7][8][9][10][11] In addition to their established efficacy for treating depression and anxiety, 12 serotonin selective reuptake inhibitors (SSRIs) have shown promise in trials for conversion or somatoform disorders 11,13 and some personality disorders. 14 These frequently occurring comorbidities in patients with PNES 15 make SSRIs particularly attractive as a potential treatment for patients with PNES.…”

mentioning

confidence: 99%

Pilot pharmacologic randomized controlled trial for psychogenic nonepileptic seizures

LaFrance¹,

Keitner²,

Papandonatos³

et al. 2010

Neurology

148

View full text Add to dashboard Cite

Objective: There have been few treatment trials for psychogenic nonepileptic seizures (PNES).Some psychotherapies have been shown to improve PNES and comorbid symptom outcomes. We evaluated a pharmacologic intervention to test the hypothesis that sertraline would reduce PNES. Methods:We conducted a pilot, double-blind, randomized, placebo-controlled trial in an academic medical hospital with epilepsy center outpatients. Subjects aged 18 to 65 years diagnosed with video-EEG-confirmed PNES were treated with flexible-dose sertraline or placebo over 12 weeks. Seizure calendars and symptom scales were charted prospectively. Secondary outcome measures included psychiatric symptom scales and psychosocial variables.Results: Thirty-eight subjects enrolled, and 26 (68%) completed the trial. Thirty-three subjects with nonzero nonepileptic seizure rates at baseline were included in intent-to-treat analysis of the primary outcome. Subjects assigned to the sertraline arm experienced a 45% reduction in seizure rates from baseline to final visit (p ϭ 0.03) vs an 8% increase in placebo (p ϭ 0.78). Secondary outcome scales revealed no significant between-group differences in change scores from baseline to final visit, after adjustment for differences at baseline.Conclusions: PNES were reduced in patients treated with a serotonin selective reuptake inhibitor, whereas those treated with placebo slightly increased. This study provides feasibility data for a larger-scale study. Level of evidence:This study provides Class II evidence that flexible-dose sertraline up to a maximum dose of 200 mg is associated with a nonsignificant reduction in PNES rate compared with a placebo control arm (risk ratio 0.51, 95% confidence interval 0.25-1.05, p ϭ 0.29), adjusting for differences at baseline. Neurology ® 2010;75:1166-1173 GLOSSARY AED ϭ antiepileptic drug; CI ϭ confidence interval; DSM-IV ϭ Diagnostic and Statistical Manual of Mental Disorders, 4th edition; ES ϭ epileptic seizures; ITT ϭ intent to treat; PNES ϭ psychogenic nonepileptic seizures; PTSD ϭ posttraumatic stress disorder; QOL ϭ quality of life; RCT ϭ randomized controlled trial; RIH ϭ Rhode Island Hospital; RR ϭ risk ratio; SSRI ϭ serotonin selective reuptake inhibitor; vEEG ϭ video-EEG.

show abstract

mentioning

confidence: 99%

Pilot pharmacologic randomized controlled trial for psychogenic nonepileptic seizures

LaFrance¹,

Keitner²,

Papandonatos³

et al. 2010

Neurology

148

View full text Add to dashboard Cite

show abstract

“…This character of the drug is confirmed by human data primarily from placebo-controlled clinical trials for the indications of general anxiety disorder and somatoform disorders [8,9], as well as by pharmacopsychological experiments [10]. In the placebocontrolled experimental study by Janke et al [10], healthy volunteers received a single dose of only 50 mg opipramol and anxiety was induced by using the paradigm of public speaking.…”

Section: Introductionmentioning

confidence: 90%

Effects of Opipramol as an Evening Anaesthesiologic Premedication

Gerlach

Uhlig²,

Plathof³

et al. 2002

Neuropsychobiology

Self Cite

View full text Add to dashboard Cite

To date, opipramol has not been examined within the context of evening premedication in anaesthesiology. A suitable drug for such an application should induce anxiolytic and sleep-favouring effects. Due to its pharmacological properties, one would expect opipramol to lead to these effects. In order to test this possibility, 72 female patients were randomly assigned to 50 mg opipramol, 100 mg opipramol, or placebo (n = 24 patients per group) in the evening prior to surgery in a double-blind trial. Effects were recorded in the morning prior to the operation by means of self-rating questionnaires, regarding the patients’ current subjective state and their judgement of the quality of sleep during the night before. The self-rating was done by the Multidimensional Mood Inventory BSKE (EWL), by use of the Multidimensional Somatic Symptom List (MSKL), and by use of the Würzburg Sleep Questionnaire. Further dependent variables were heart rate and blood pressure. Opipramol significantly improved sleep quality. Especially the frequency of awakening at night was reduced. These effects could be observed predominantly after 100 mg opipramol. At this dosage, inner excitement was reduced as well. The autonomic variables remained uninfluenced. There were no adverse events and no hints for interactions with anaesthesiology.

show abstract

“…as research suggest, patients' expectations for the behavior of a physician are different. according to zimmer- Paroxetine 20 mg [76] moclobemide 300 mg (i-mao-a) [77] sertraline 50 mg [78] trazodone 150 mg (sari) [79] Venlafaxine 75 mg (snri) [80] amitriptyline 75 mg (tCa) [81] Clomipramine 150 mg (tCa) [82] opipramol 200 mg (tCa) [83] doxepine 100 mg (tCa) [84] Vortioxetine 10 mg (sms) [85] Bupropion 150 mg (ndri) [86] man et al, the importance of patients' expectations is as follows: 1) the presence of mental health symptoms (e.g. optimism, vigor, self-confidence); 2) sense of normality; 3) return to normal functioning at work, home; 4) the feeling of emotional control; 5) relationships with family and friends and the ability to enjoy them; 6) the lack of symptoms of depression -as the last element of the psychopathological picture [87].…”

Section: Treatment Of Depressionmentioning

confidence: 99%

Guidelines of the Polish Psychiatric Association – Wroclaw Division, the Polish Society of Family Medicine and the College of Family Physicians in Poland for diagnosis and treatment of depressive disorders in primary health care

Piotrowski¹,

Gondek²,

Rymaszewska³

et al. 2017

fmpcr

View full text Add to dashboard Cite

Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial

Cited by 91 publications

References 16 publications

Pilot pharmacologic randomized controlled trial for psychogenic nonepileptic seizures

Pilot pharmacologic randomized controlled trial for psychogenic nonepileptic seizures

Effects of Opipramol as an Evening Anaesthesiologic Premedication

Guidelines of the Polish Psychiatric Association – Wroclaw Division, the Polish Society of Family Medicine and the College of Family Physicians in Poland for diagnosis and treatment of depressive disorders in primary health care

Contact Info

Product

Resources

About